[1]Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments[J]. Neurotherapeutics, 2009, 6(4): 638-647.
[2]Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats[J]. Free Radic Biol Med, 2001, 31(1): 125-135.
[3]Obrosova IG, Drel VR, Oltman CL, et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats[J]. Am J Physiol Endocrinol Metab, 2007, 293(6): E1645-1655.
[4]Giniatullin R, Nistri A. Desensitization properties of P2X3 receptors shaping pain signaling[J]. Front Cell Neurosci, 2013, 7: 245.
[5]Wirkner K, Sperlagh BP, Illes P. P2X3 receptor involvement in pain states[J]. Mol Neurobiol, 2007, 36(2): 165-183.
[6]North RA. P2X3 receptors and peripheral pain mechanisms[J]. J Physiol, 2004, 554(Pt 2): 301-308.
[7]Tu WZ, Cheng RD, Cheng B, et al. Analgesic effect of electroacupuncture on chronic neuropathic pain mediated by P2X3 receptors in rat dorsal root ganglion neurons[J]. Neurochem Int, 2012, 60(4): 379-386.
[8]Liu M, Yang H, Fang D, et al. Upregulation of P2X3 receptors by neuronal calcium sensor protein VILIP1 in dorsal root ganglions contributes to the bone cancer pain in rats[J]. Pain, 2013, 154(9): 1551-1568.
[9]Wu JX, Xu MY, Miao XR, et al. Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain[J]. Eur J Pain, 2012, 16(10): 1378-1388.
[10]Migita K, Moriyama T, Koguchi M, et al. Modulation of P2X receptors in dorsal root ganglion neurons of streptozotocin-induced diabetic neuropathy[J]. Neurosci Lett, 2009, 452(2): 200-203.
[11]Xu GY, Li G, Liu N, et al. Mechanisms underlying purinergic P2X3 receptor-mediated mechanical allodynia induced in diabetic rats[J]. Mol Pain, 2011, 7: 60.
[12]Kamiya H, Zhang W, Ekberg K, et al. C-Peptide reverses nociceptive neuropathy in type 1 diabetes[J]. Diabetes, 2006, 55(12): p. 3581-3587.
[13]Zhang W, Murakawa Y, Wozniak KM, et al. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy[J]. J Neurol Sci, 2006, 247(2): 217-223.
[14]Kim SH, Kwon JK, Kwon YB, et al. Pain modality and spinal glia expression by streptozotocin induced diabetic peripheral neuropathy in rats[J]. Lab Anim Res, 2012, 28(2): 131-136.
[15]Kaan TK, Yip PK, Patel S, et al. Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats[J]. Brain, 2010, 133(9): 2549-2564.
[16]McGaraughty S, Wismer CT, Zhu CZ, et al. Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration[J]. Br J Pharmacol, 2003, 140(8): 1381-1388.
[17]Tsuda M, Koizumi S, Kita A, et al. Mechanical allodynia caused by intraplantar injection of P2X receptor agonist in rats: involvement of heteromeric P2X2/3 receptor signaling in capsaicin-insensitive primary afferent neurons[J]. J Neurosci, 2000, 20(15): RC90.
[18]Ou S, Zhao YD, Xiao Z, et al. Effect of lappaconitine on neuropathic pain mediated by P2X3 receptor in rat dorsal root ganglion[J]. Neurochem Int, 2011, 58(5): 564-573.
[19]Kage K, Niforatos W, Zhu CZ, et al. Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat[J]. Exp Brain Res, 2002, 147(4): 511-519.
[20]Chen Y, Li GW, Wang C, et al. Mechanisms underlying enhanced P2X receptor-mediated responses in the neuropathic pain state[J]. Pain, 2005, 119(1-3): 38-48. |